Milestone Achievement and Market Context
On 10 June 2026, Integrated Proteins Ltd’s share price closed at Rs.142.80, setting a new 52-week and all-time high. This price level represents a substantial increase from its 52-week low of Rs.20.71, reflecting a gain of approximately 589.5% from the lowest point in the past year. The stock’s performance on the day was steady, with no change recorded, while it outperformed its sector, Solvent Extraction, which declined by 3.19%.
The company’s stock has consistently traded above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a robust bullish trend. This technical strength is further supported by a series of bullish indicators such as MACD, Bollinger Bands, KST, and Dow Theory on both weekly and monthly timeframes, despite a bearish RSI on the weekly chart.
Performance Analysis Over Various Timeframes
Integrated Proteins Ltd has demonstrated exceptional returns across multiple time horizons, significantly outpacing the broader Sensex index. Over the past one year, the stock surged by 222.35%, while the Sensex declined by 9.64%. Year-to-date, the stock’s performance is even more striking, with a gain of 315.12% compared to the Sensex’s fall of 12.63%. The three-month return stands at an impressive 197.50%, contrasting with the Sensex’s negative 4.80% over the same period.
Longer-term performance also highlights the company’s remarkable growth trajectory. Over three years, Integrated Proteins Ltd’s stock price appreciated by 1,323.73%, vastly outperforming the Sensex’s 18.89% gain. The ten-year performance is particularly notable, with a staggering increase of 6,572.90%, dwarfing the Sensex’s 179.52% rise. These figures underscore the company’s sustained value creation over an extended period.
Valuation Metrics and Financial Ratios
At the current price of Rs.142.80, Integrated Proteins Ltd’s valuation multiples reflect a premium positioning. The trailing twelve months (TTM) price-to-earnings (P/E) ratio stands at 545x, indicating high market expectations relative to earnings. The price-to-book value (P/BV) ratio is 13.02x, while the enterprise value to EBITDA and EBIT ratios are both at 267.25x, signalling elevated valuation levels.
The enterprise value to sales ratio is 27.02x, and the EV to capital employed ratio is 13.00x. Dividend metrics are not applicable as the company has not declared dividends recently, with a dividend payout ratio of zero. Overall valuation data is not available, but these multiples suggest the market is pricing in significant growth and operational strength.
Quality Assessment and Financial Health
Integrated Proteins Ltd is classified as an average quality company based on its long-term financial performance. The management risk is considered below average, while growth and capital structure are rated average and good, respectively. The company has demonstrated a healthy five-year sales compound annual growth rate (CAGR) of 61.22%, though EBIT growth over the same period is more modest at 6.65%.
Financial leverage remains low, with an average debt to EBITDA ratio of 0.46 and net debt to equity at zero, indicating a strong balance sheet with negligible debt. The company has no promoter share pledging, and institutional holdings are minimal. Return on capital employed (ROCE) and return on equity (ROE) are relatively weak at -4.21% and 2.06%, respectively, reflecting areas for improvement in profitability metrics.
Technical Trend and Market Activity
The stock’s overall technical trend is bullish, a shift that occurred on 27 March 2026 when the price was at Rs.71.33. Since then, the stock has maintained upward momentum, supported by strong technical indicators. Immediate support is identified at the 52-week low of Rs.20.71, while resistance levels previously existed around Rs.132.43 (20-day moving average) and Rs.72.88 (100-day moving average), both of which have been surpassed as the stock reached its new high.
Delivery volumes have shown a marked increase, with a 1-day delivery change of 466.81% compared to the five-day average, and a 1-month delivery volume increase of 50.47%. This heightened trading activity reflects growing market participation and liquidity in the stock.
Short-Term Financial Trends
Recent financial trends indicate a flat short-term performance as of March 2026. The company reported a higher profit after tax (PAT) of ₹0.26 crores for the nine-month period, signalling positive earnings momentum. However, net sales for the latest six months stood at ₹5.69 crores, reflecting a decline of 73.53%, which suggests some variability in revenue generation during this period.
Summary of Integrated Proteins Ltd’s Journey to the Peak
Integrated Proteins Ltd’s ascent to its all-time high price of Rs.142.80 is the culmination of years of robust sales growth, improving market sentiment, and technical strength. The stock’s performance has consistently outpaced the broader market and its sector peers, supported by a strong balance sheet and low leverage. While valuation multiples are elevated, they reflect the market’s recognition of the company’s growth trajectory and operational resilience.
Despite some challenges in recent sales figures and modest profitability ratios, the company’s long-term growth story remains intact, as evidenced by its extraordinary returns over the past decade. The stock’s technical indicators and delivery volumes further reinforce the positive momentum that has propelled it to this historic price level.
